DARPA ATP Phase 2: Characterization of an Anti-HA33A TXscAb Antibody Produced by the University of Texas
Abstract
The Defense Advanced Research Projects Agency (DARPA; Arlington, VA) Antibody Technology Program (ATP) develops technologies that enhance both the thermal stability and binding affinity of given antibodies. In this study, the U.S. Army Edgewood Chemical Biological Center (ECBC; Aberdeen Proving Ground, MD) functioned as an independent testing laboratory to provide technical support on immune reagents as well as assistance in defining the government-supplied antibody-antigen pairs. The goals of this project were to implement standardized methods for characterizing antibodies developed at ECBC with the de novo thermal and binding properties of select reagents to be used in the future by DARPA-funded investigators. Investigators will then use those methods to validate changes in antibody thermal stability and binding affinities. The antibody chosen for enhancement was Bot 56, which detects hemagglutinin-33/A (a part of the botulinum neurotoxin complex type A). The focus of this work was to evaluate the Bot antibody supplied by the DARPA-funded investigator University of Texas (Austin, TX) for affinity and stability enhancements. Results from this study provide standardized parametric data on the antibody properties and performance to support selection of antibody-based reagents that optimize field operational and performance metrics of future detection and diagnostic platforms.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2023
- Accession Number
- AD1199379
Entities
People
- Alena M. Calm
- Candice Warner
- Darrel Menking
- Heather Welsh
- James Carney
- Melody Zacharko
- Patricia E. Buckley
- Roy Thompson